Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
WINLEVI works differently from any other topical acne treatment
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Subscribe To Our Newsletter & Stay Updated